Noticeably, among all CDK4/6 inhibitors analyzed, which are newly approved as first line drugs in breast cancer in recent years, the IC50 of Palbociclib (Figure 7A,B), and Ribociclib (Figure 7C) were positively correlated with the risk score. Here, CDK4 is linked to breast cancer.